Guldvik, I.J.; Ekseth, L.; Kishan, A.U.; Stensvold, A.; Inderberg, E.M.; Lilleby, W.
Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer. J. Pers. Med. 2021, 11, 605.
https://doi.org/10.3390/jpm11070605
AMA Style
Guldvik IJ, Ekseth L, Kishan AU, Stensvold A, Inderberg EM, Lilleby W.
Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer. Journal of Personalized Medicine. 2021; 11(7):605.
https://doi.org/10.3390/jpm11070605
Chicago/Turabian Style
Guldvik, Ingrid Jenny, Lina Ekseth, Amar U. Kishan, Andreas Stensvold, Else Marit Inderberg, and Wolfgang Lilleby.
2021. "Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer" Journal of Personalized Medicine 11, no. 7: 605.
https://doi.org/10.3390/jpm11070605
APA Style
Guldvik, I. J., Ekseth, L., Kishan, A. U., Stensvold, A., Inderberg, E. M., & Lilleby, W.
(2021). Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer. Journal of Personalized Medicine, 11(7), 605.
https://doi.org/10.3390/jpm11070605